<i>CYP3A4*22</i> may increase bleeding risk in ticagrelor users-Reference-Cited by-同舟云学术

CYP3A4*22 may increase bleeding risk in ticagrelor users

Published:2023-05-31 Issue:2 Volume:133 Page:202-207
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharma Tox

Author:

Liedes Hilkka¹^ORCID,Pajula Juha²^ORCID,Vuorinen Anna‐Leena²^ORCID,De Pretis Francesco³^ORCID,van Gils Mark²^ORCID,Harno Kari⁴,Lehto Mika⁵⁶^ORCID,Niemi Mikko⁷⁸^ORCID,Lähteenmäki Jaakko⁹^ORCID

Affiliation:

1. VTT Technical Research Centre of Finland Ltd. Oulu Finland

2. VTT Technical Research Centre of Finland Ltd. Tampere Finland

3. VTT Technical Research Centre of Finland Ltd. Kuopio Finland

4. Department of Health and Social Management University of Eastern Finland Kuopio Finland

5. Heart and Lung Center Helsinki University Hospital Helsinki Finland

6. Faculty of Medicine, Clinicum University of Helsinki Helsinki Finland

7. Department of Clinical Pharmacology and Individualized Drug Therapy Research Program University of Helsinki Helsinki Finland

8. Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital Helsinki Finland

9. VTT Technical Research Centre of Finland Ltd. Espoo Finland

Funder

Business Finland

Teknologian Tutkimuskeskus VTT

European Research Consortium for Informatics and Mathematics

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13884

Reference10 articles.

1. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety

2. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

3. PharmGKB summary

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin;Personalized Medicine;2024-04-29

2. CYP3A4*22 and bleeding risk in ticagrelor users;Basic & Clinical Pharmacology & Toxicology;2024-01-10

3. Advances and Perspectives in methods for identifying high platelet reactivity;Heliyon;2023-12

4. Pharmacogenomics of Cardiovascular Diseases: The Path to Precision Therapy;Pharmacogenomics and Pharmacogenetics in Drug Therapy [Working Title];2023-10-14